Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.54M Buy
4,256
+3,454
+431% +$1.18M 0.56% 44
2026
Q1
$282K Buy
802
+2
+0.3% +$713 0.12% 104
2025
Q4
$262K Sell
800
-264
-25% -$83.7K 0.11% 106
2025
Q3
$300K Buy
1,064
+69
+7% +$20K 0.13% 99
2025
Q2
$278K Sell
995
-313
-24% -$88.7K 0.13% 103
2025
Q1
$407K Buy
1,308
+275
+27% +$81.2K 0.22% 66
2024
Q4
$269K Buy
1,033
+111
+12% +$32.9K 0.14% 80
2024
Q3
$297K Buy
922
+1
+0.1% +$327 0.16% 70
2024
Q2
$288K Buy
+921
New +$271K 0.16% 73
2023
Q4
Sell
-974
Closed -$262K 110
2023
Q3
$262K Sell
974
-370
-28% -$92.3K 0.19% 95
2023
Q2
$298K Buy
+1,344
New +$312K 0.21% 85

Other funds holding AMGN

MRA Advisory Group's AMGN Position: Q2 2026 in Review

MRA Advisory Group increased its Amgen (AMGN) stake by 431% in Q2 2026, buying an estimated $1.18M and bringing the position to 4,256 shares worth $1.54M. The position accounts for 0.56% of the portfolio, ranked #44.

MRA Advisory Group first reported a position in AMGN in Q2 2023 and has held it in 11 quarters since. 1,055 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • MRA Advisory Group held 4,256 shares of Amgen worth $1.54M as of Q2 2026.
  • MRA Advisory Group bought 3,454 Amgen shares in Q2 2026, an estimated $1.18M.
  • Amgen made up 0.56% of MRA Advisory Group's portfolio in Q2 2026, its #44 holding.
  • MRA Advisory Group first reported a position in Amgen in Q2 2023 and has held it in 11 quarters since.
  • 1,055 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on MRA Advisory Group's 13F filing for Q2 2026, filed 8 Jul 2026.